Keywords: Liver, Cancer
Motivation: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the third leading cause of cancer-related death.
Goal(s): This study investigated the value of gadobenate dimeglumine-enhanced quantitative parameters for predicting the proliferative subtype of HCC and patients’ prognosis.
Approach: All HCC lesions were resected and pathologically confirmed. The lesion-to-liver contrast enhancement ratio (LLCER) was measured in the hepatobiliary phase.
Results: LLCER was identified as an independent predictor of proliferative HCC. Patients with LLCER < -4.59% had a significantly higher incidence of proliferative HCC. In addition, patients with LLCER < -4.61% showed poorer overall survival than those with LLCER ≥ -4.61%.
Impact: Quantitative information from gadobenate dimeglumine–enhanced MRI can provide crucial information on hepatocellular carcinoma subtypes. It might be valuable to design novel therapeutic strategies, such as targeted therapies or immunotherapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords